Shares of both Henry Schein (NASDAQ:HSIC) and its new partner Masimo Corporation (NASDAQ:MASI) move higher, as they announce an agreement in which the former will distribute the latter’s Masimo’s Pronto-7, which is the sole FDA approved small non-invasive device for spot-checking of total hemoglobin, SpO2, pulse rate and perfusion index.
Don’t Miss: Have Shorts CONQUERED Dendreon’s Stock?
Questcor (NASDAQ:QCOR) shares benefit from positive comments originating in its conference call Friday, for the discussion of the commercialization of its rheumatology drug, Acthar. Analysts were in agreement, with Oppenheimer commenting that it’s well encouraged by not only the med’s prospects, but also the company’s ease in implementing its strategy; and both Caris and Jefferies arguing that Street estimates fail to factor in the drug effectively, thus it will have to move higher.
Any purchase bids for Amylin (NASDAQ:AMLN) would have to be at a minimum in a range of the low to mid $30s, says Jefferies, following a meeting with company management. The analysts believe that the firm will start to be pressured to make strategic decisions regarding possible acquisitions by September, and maintain their Buy with a price target of $32.
Don’t Miss: Were Feds Suspicious of Facebook BEFORE the IPO?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.